We see a growing number of small biotechs that choose to bring their products to the market themselves. In this article we explain how a CDMO can help them navigate clinical CMC hurdles, including bioprocess scale-up and preparing for what may be their first-ever BLA filing.
Read this article
Latest content
Latest briefing from the Knowledge Center